AFT Pharmaceuticals - Maxigesic IV hits a roadblock in the US
In an unexpected development, AFT Pharmaceuticals (AFT) has announced that it has received a complete response letter (CRL) from the United States...
729 Views
AFT Pharmaceuticals - Re-acceleration leveraging its platform
Overcoming COVID-19 headwinds, AFT Pharmaceuticals reported strong FY22 year results, largely driven by management’s ability to leverage its broad...
750 Views
AFT Pharmaceuticals - Recovery driven by strong H222
AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid...
725 Views
AFT Pharmaceuticals - 14% revenue growth despite COVID-19 headwinds
AFT Pharmaceuticals recently reported its results for H122. Operating revenue grew strongly by 14% year-on-year to NZ$55.5m, despite the impact of...
832 Views
AFT Pharmaceuticals - Growth in the face of a challenging environment
AFT Pharmaceuticals recently reported its results for FY21. Operating revenue grew strongly by 7% year-on-year to NZ$113.1m, driven mainly by 11%...
623 Views